Short answer
CapsoVision, Inc (CV) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $4M (up 0.8% year over year) with net income of −$7M.
Q3 2026 key financials · XBRL
- Revenue
- $4M
- +0.8% YoY · −2.1% QoQ
- Net income
- −$7M
- +7.3% YoY · +1.9% QoQ
- Operating margin
- -207.0%
- Gross margin
- 49.4%
- EPS (diluted)
- −$0.14
- −104.1% YoY · +6.7% QoQ
Source: XBRL data from the CapsoVision, Inc (CV) Q3 2026 10-Q on SEC EDGAR. USD.
CapsoVision, Inc Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $3.568M, up $0.030M, approximately 1% YoY, driven by international CapsoCam Plus sales
- Gross margin 49% vs 54% YoY, with gross profit $1.764M vs $1.914M
- International sales strongest, up 8%; U.S. sales weakest, down 1%
- Operating cash use $21.5M through nine months vs $15.2M YoY, with $21.8M cash at September 30
- CapsoCam Colon 510(k) submission expected fourth quarter 2026, with substantial doubt about funding operations for 12 months
Risk Factors
- New regulatory risk: OBBBA Medicaid reforms, including estimated $1 trillion federal spending reduction from 2025 through 2034
- Most material update: substantial doubt about going concern, cash $21.8 million and additional financing likely needed by early 2027
- FDA clearance risk: second-generation CapsoCam Colon 510(k) submission planned for fourth quarter 2026, with FDA staff reductions potentially causing delays
- Competitive risk: Ankon’s FDA-cleared small-bowel AI launched before AI Highlights, potentially reducing market share and revenue opportunities
- Concentration risk: Aureliance represented 11% of nine-month revenue and 23% of accounts receivable at September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CapsoVision, Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.